论文部分内容阅读
目的从分子水平探讨阿魏酸钠治疗各类肾小球疾病所引起的蛋白尿的可能机制。方法确诊为系膜增生性肾小球肾炎以蛋白尿为主要表现的患者43例,随机分为阿魏酸钠治疗组(n=26例,阿魏酸钠0.5g加入5%葡萄糖250ml静滴,每日1次)、丹参对照组(n=17例,丹参30ml加入5%葡萄糖250ml静滴,每日1次),两组均以28天为1疗程,分别于治疗前及治疗后行经皮肾活检,留取肾组织行Nrothern blot及Western blot以检测治疗前后肾组织中内皮素-1(ET-1)的表达差异。结果阿魏酸钠治疗后患者肾组织中ET-1的mRNA及蛋白水平的表达较治疗前显著下降(P=0.0076、P=0.0093)。结论阿魏酸钠可从mRNA及蛋白水平抑制肾组织中ET-1的表达,进而减少尿蛋白,保护肾功能。
Objective To investigate the possible mechanism of sodium ferulate in treating various types of glomerular diseases caused by proteinuria at the molecular level. Methods Forty-three patients diagnosed as mesangial proliferative glomerulonephritis with proteinuria were randomly divided into two groups: sodium ferulate (n = 26, 0.5g sodium ferulate, 250ml infusion of 5% glucose) , Once a day), Salvia miltiorrhiza control group (n = 17, Danshen 30ml added 5% glucose 250ml intravenous drip once daily), two groups were 28 days for a course of treatment, respectively, before and after treatment The renal biopsies were collected and the renal tissues were collected for the detection of endothelin-1 (ET-1) expression by Nrothern blot and Western blot. Results After treatment with sodium ferulate, ET-1 mRNA and protein levels were significantly decreased in renal tissue (P = 0.0076, P = 0.0093). Conclusion Sodium ferulate can inhibit the expression of ET-1 in renal tissue from the mRNA and protein levels, thereby reducing the urinary protein and protecting renal function.